Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Junyuan WANG
Junyuan WANG

Founder, President & CEO


AnHeart Therapeutics Inc.

Dr. Junyuan Wang is a founder of AnHeart Therapeutics Inc. Dr. Wang has strong leadership experience in global clinical development and medical research acquired through his work at Merck Serono, BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. His broad drug development experiences including therapeutic areas such as oncology, cardiovascular, neuroscience, immunology, and hematology. He has a stellar track-record in shaping global drug development strategy. He has played critical support for two successful new drug applications in US and worldwide market authorization. One of the product that he led a team of over 20 people to support NDA has reached annual sale of USD 5 Billion in 2017. He also played critical role in many submissions for label extensions. Besides many interaction with health authorities including FDA, EMA, PMDA and CFDA, he also has rich experience in partnering with key opinion leaders and vendors to foster data-driven decision making.  He is well recognized for his deep understanding in ICH guidelines, GCP compliance, and trial quality control. He serves as global experts for two CFDA/CDE ICH working groups. He also served leadership role in professional societies and in programming committee of scientific conferences.